A ICE Pharma lança o projeto «Check-up your bias» para promover a igualdade de género no local de trabalho
Bias, especially in the workplace, affects all of us. Even if we are willing to give the best of ourselves, sometimes we unknowingly engage in different behaviors according to...
Quarta publicação de investigação em colaboração com a ICE Pharma e o Ferrier Research Institute
We are proud to announce the publication of another scientific paper coming from the collaboration of ICE Pharma with the Ferrier Research Institute. This paper relates to Parkinson’s Disease...
A ICE Pharma obteve as certificações ISO 45001 e ISO 50001 nas suas instalações na Itália e na Nova Zelândia.
Desde o planeamento, a construção e a operação das instalações de produção, continuamos a implementar normas globais de segurança de processos e a melhorar as medidas de prevenção de incidentes em todas as nossas fábricas em todo o mundo....
A recent study suggest that UDCA may help prevent Covid infection
ICE Pharma has been featured in an article in the Italian press, Il corriere della sera, concerning the huge increase in requirement for the drug Ursodeoxycholic acid in China. ...
New Zealand Pharmaceuticals achieved the FernMark license
It’s with great pleasure that we announce the achievement by our subsidiary, NZP, of the renowned FernMark license. The FernMark is a mark of trust that communicates a product’s...
A ICE Pharma publicou o Relatório de Sustentabilidade 2021/2022
During 2022, ICE Pharma developed a long-term sustainability strategy and a short-term roadmap that will guide our actions for the next three years. We describe the strategic choices that...
A ICE Pharma adquire a unidade de produção de Iwaki à Mitsubishi API Corporation
We are pleased to announce that on May 2nd ICE Pharma completed the purchase of the Iwaki Ursodeoxycholic Acid (“UDCA”) manufacturing site from Mitsubishi API Corporation. This transaction represents...
Third research publication in collaboration with ICE Pharma and Ferrier Research Institute
Synthesis of Novel C/D Ring Modified Bile Acids Bile acid receptors have been identified as important targets for the development of new therapeutics to treat various metabolic and inflammatory...
Ácidos biliares na medicina. Artigo de revisão da ICE Pharma
Bile acids: From ancient Chinese medicines to modern treatments In 1999 the landscape evolved further when, bile acids and bile salts were shown to have hormonal activity as bile...
Segunda publicação científica em colaboração com a ICE Pharma e o Ferrier Research Institute
Synthesis of 12β-methyl-18-nor-avicholic acid analogues as potential TGR5 agonists In the quest for new modulators of the Farnesoid-X (FXR) and Takeda G-protein-coupled (TGR5) receptors, bile acids are a popular...
A ICE Pharma adquire a ABC Farmaceutici S.p.A.
Temos o prazer de anunciar que, no dia 15 de dezembro, a ICE Pharma concluiu a aquisição da ABC Farmaceutici S.p.A. («ABC»). A ABC é uma empresa farmacêutica sediada em Ivrea, Itália. Fundada...
First research publication in collaboration with ICE Pharma and Ferrier Research Institute
Synthesis of 12β-Methyl-18-nor-bile Acids Decoupling the roles of the farnesoid X nuclear receptor and Takeda G-protein-coupled bile acid receptor 5 is essential for the development of novel bile acid...